Negative Findings Reported in ENGOT-EN1 Endometrial Cancer Study Led by Kristina Lindemann
Kristina Lindemann, Head of the Gynecological Oncology Center at Oslo University Hospital, shared a post on LinkedIn about a paper she co-authored with colleagues published in Gynecologic Oncology:
“In a rapidly changing treatment landscape, we have finally published the results of the FIRST in a long row of ENGOT endometrial cancer studies.
NSGO-FANDANGO/ENGOT-EN1 did not show any benefit in adding nintedanib/placebo to platinum-based chemotherapy. Sometimes results are already history at the time of publication, but still important to have negative studies published.
Thanks to all ENGOT investigators, site staff, the NSGO-CTU office, as well as patients and their families who contributed to the study.”
Title: NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer
Authors: Kristina Lindemann, Dominique Berton, Jalid Sehouli, René DePont Christensen, Sevilay Altintas, Anja Ør Knudsen, Pierre-Etienne Heudel, Beyhan Ataseven, Ignace Vergote, Gabriel Lindahl, Coriolan Lebreton, Fabienne Schochter, Annika Auranen, Philippe Follana, Kristine Madsen, Frédéric Selle, Karen Stampe Petersson, Florence Joly, Elena Ioana Braicu, Mansoor Raza Mirza.
You can read the Full Article in Gynecologic Oncology.
More posts featuring Kristina Lindemann.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023